NBIX Neurocrine Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NBIX

Price (delayed)

$119.44

Market cap

$11.74B

P/E Ratio

60.94

Dividend/share

N/A

EPS

$1.96

Enterprise value

$11.7B

Neurocrine Biosciences is a publicly traded biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological ...

Highlights
The price to earnings (P/E) is 64% lower than the 5-year quarterly average of 165.7 and 28% lower than the last 4 quarters average of 83.5
The company's equity rose by 30% YoY and by 8% QoQ
Neurocrine Biosciences's quick ratio has decreased by 6% from the previous quarter and by 3.5% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.neurocrine.com/
Peers: RGEN RPRX ABBV PTN

Key stats

What are the main financial stats of NBIX
Market
Shares outstanding
98.25M
Market cap
$11.74B
Enterprise value
$11.7B
Valuations
Price to earnings (P/E)
60.94
Price to book (P/B)
5.83
Price to sales (P/S)
6.55
EV/EBIT
45.62
EV/EBITDA
42.32
EV/Sales
6.56
Earnings
Revenue
$1.78B
EBIT
$256.4M
EBITDA
$276.4M
Free cash flow
$384.7M
Per share
EPS
$1.96
Free cash flow per share
$3.93
Book value per share
$20.5
Revenue per share
$18.22
TBVPS
$28.74
Balance sheet
Total assets
$2.85B
Total liabilities
$846.1M
Debt
$255.8M
Equity
$2B
Working capital
$958.3M
Liquidity
Debt to equity
0.13
Current ratio
2.39
Quick ratio
2.19
Net debt/EBITDA
-0.14
Margins
EBITDA margin
15.5%
Gross margin
97.8%
Net margin
10.7%
Operating margin
11.4%
Efficiency
Return on assets
7.5%
Return on equity
10.5%
Return on invested capital
12.7%
Return on capital employed
11.9%
Return on sales
14.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NBIX stock price

How has the Neurocrine Biosciences stock price performed over time
Intraday
0.76%
1 week
5.2%
1 month
4.76%
1 year
-0.64%
YTD
0%
QTD
6.17%

Financial performance

How have Neurocrine Biosciences's revenue and profit performed over time
Revenue
$1.78B
Gross profit
$1.75B
Operating income
$204M
Net income
$191M
Gross margin
97.8%
Net margin
10.7%
The net margin has soared by 155% YoY
The operating income has surged by 87% year-on-year and by 35% since the previous quarter
The operating margin has grown by 44% YoY and by 27% from the previous quarter
Neurocrine Biosciences's revenue has increased by 28% YoY and by 7% QoQ

Growth

What is Neurocrine Biosciences's growth rate over time

Valuation

What is Neurocrine Biosciences stock price valuation
NBIX P/E details
P/E
60.94
P/B
5.83
P/S
6.55
EV/EBIT
45.62
EV/EBITDA
42.32
EV/Sales
6.56
The price to earnings (P/E) is 64% lower than the 5-year quarterly average of 165.7 and 28% lower than the last 4 quarters average of 83.5
NBIX's EPS is up by 7% since the previous quarter
NBIX's price to book (P/B) is 40% lower than its 5-year quarterly average of 9.6
The company's equity rose by 30% YoY and by 8% QoQ
The stock's price to sales (P/S) is 30% less than its 5-year quarterly average of 9.3
Neurocrine Biosciences's revenue has increased by 28% YoY and by 7% QoQ

Efficiency

How efficient is Neurocrine Biosciences business performance
Neurocrine Biosciences's return on assets has surged by 168% YoY
The ROE has soared by 156% YoY
The company's return on invested capital has surged by 154% YoY and by 2.4% QoQ
NBIX's return on sales has surged by 112% year-on-year

Dividends

What is NBIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NBIX.

Financial health

How did Neurocrine Biosciences financials performed over time
The total liabilities has grown by 41% YoY and by 11% from the previous quarter
NBIX's total assets is up by 33% YoY and by 9% from the previous quarter
The debt is 87% lower than the equity
The company's equity rose by 30% YoY and by 8% QoQ
NBIX's debt to equity is down by 24% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.